Replimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Barclays PLC

Barclays PLC boosted its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL) by 165.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 158,491 shares of the company’s stock after purchasing an additional 98,791 shares during the period. Barclays PLC owned approximately 0.23% of Replimune Group worth $1,738,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. Bank of New York Mellon Corp boosted its stake in shares of Replimune Group by 10.7% during the second quarter. Bank of New York Mellon Corp now owns 180,226 shares of the company’s stock worth $1,622,000 after buying an additional 17,471 shares during the period. Rhumbline Advisers lifted its position in Replimune Group by 7.2% during the 2nd quarter. Rhumbline Advisers now owns 84,923 shares of the company’s stock worth $764,000 after acquiring an additional 5,732 shares during the period. TD Asset Management Inc grew its stake in shares of Replimune Group by 4.6% in the 2nd quarter. TD Asset Management Inc now owns 249,940 shares of the company’s stock valued at $2,249,000 after purchasing an additional 11,094 shares during the last quarter. Arizona State Retirement System acquired a new position in shares of Replimune Group in the second quarter valued at approximately $108,000. Finally, Los Angeles Capital Management LLC increased its holdings in shares of Replimune Group by 8.1% in the second quarter. Los Angeles Capital Management LLC now owns 71,815 shares of the company’s stock valued at $646,000 after purchasing an additional 5,410 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Replimune Group

In related news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the sale, the insider now directly owns 109,885 shares of the company’s stock, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the transaction, the chief executive officer now owns 202,014 shares of the company’s stock, valued at approximately $2,509,013.88. The trade was a 4.72 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company’s stock.

Replimune Group Price Performance

Shares of NASDAQ REPL opened at $12.26 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $17.00. The firm has a market capitalization of $838.79 million, a P/E ratio of -4.02 and a beta of 1.26. The company’s fifty day moving average is $12.37 and its two-hundred day moving average is $10.86.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. Analysts forecast that Replimune Group, Inc. will post -2.91 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on REPL. JPMorgan Chase & Co. increased their price target on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Jefferies Financial Group raised their target price on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. BMO Capital Markets lifted their target price on shares of Replimune Group from $14.00 to $18.00 and gave the company an “outperform” rating in a report on Friday, November 22nd. Finally, HC Wainwright reissued a “buy” rating and set a $17.00 price target on shares of Replimune Group in a report on Friday, November 22nd. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Replimune Group presently has a consensus rating of “Buy” and an average price target of $17.29.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.